LRI Investments LLC Cuts Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

LRI Investments LLC trimmed its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 39.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 572 shares of the medical research company’s stock after selling 377 shares during the period. LRI Investments LLC’s holdings in Charles River Laboratories International were worth $86,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of CRL. Vanguard Group Inc. raised its position in shares of Charles River Laboratories International by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 6,158,926 shares of the medical research company’s stock valued at $1,136,938,000 after buying an additional 60,497 shares during the last quarter. Wellington Management Group LLP raised its holdings in Charles River Laboratories International by 9.0% in the fourth quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company’s stock valued at $752,508,000 after acquiring an additional 335,658 shares in the last quarter. Geode Capital Management LLC raised its holdings in Charles River Laboratories International by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 1,233,211 shares of the medical research company’s stock valued at $227,042,000 after acquiring an additional 14,787 shares in the last quarter. Ariel Investments LLC raised its holdings in Charles River Laboratories International by 18.9% during the fourth quarter. Ariel Investments LLC now owns 1,067,327 shares of the medical research company’s stock worth $197,029,000 after purchasing an additional 169,640 shares in the last quarter. Finally, Invesco Ltd. increased its holdings in shares of Charles River Laboratories International by 17.1% in the 4th quarter. Invesco Ltd. now owns 1,034,180 shares of the medical research company’s stock valued at $190,910,000 after acquiring an additional 151,159 shares during the period. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the business’s stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the sale, the executive vice president owned 19,513 shares in the company, valued at approximately $2,837,385.33. The trade was a 2.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.30% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms recently commented on CRL. Redburn Atlantic upgraded shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and decreased their price objective for the stock from $188.00 to $182.00 in a research report on Friday, May 23rd. Robert W. Baird increased their target price on Charles River Laboratories International from $118.00 to $140.00 and gave the company a “neutral” rating in a research note on Thursday, May 8th. Evercore ISI increased their target price on Charles River Laboratories International from $170.00 to $180.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 9th. Barclays lifted their price objective on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the company an “equal weight” rating in a research note on Thursday, May 8th. Finally, TD Cowen upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $179.00 price objective for the company in a research report on Wednesday, May 14th. One analyst has rated the stock with a sell rating, eleven have given a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $174.54.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $158.09 on Tuesday. The company has a market capitalization of $7.77 billion, a PE ratio of -243.21, a P/E/G ratio of 5.40 and a beta of 1.49. The company has a 50 day simple moving average of $144.87 and a two-hundred day simple moving average of $151.35. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.16 and a current ratio of 1.43. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $254.15.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.06 by $0.28. The company had revenue of $984.17 million for the quarter, compared to analysts’ expectations of $942.34 million. Charles River Laboratories International had a positive return on equity of 15.19% and a negative net margin of 0.66%. Charles River Laboratories International’s quarterly revenue was down 2.7% compared to the same quarter last year. During the same period last year, the business earned $2.27 EPS. Research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).